These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 10800156)

  • 1. The clinical utility of epoetin in cancer patients: a matter of perspective.
    Barosi G; Marchetti M
    Haematologica; 2000 May; 85(5):449-50. PubMed ID: 10800156
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical application of recombinant erythropoietin in anemic cancer patients.
    Henry DH
    Hematol Oncol Clin North Am; 1994 Oct; 8(5):961-73. PubMed ID: 7852218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin: can we afford to use it? Can we afford not to?
    Laird J
    Transfus Med; 2006 Jun; 16(3):204-5. PubMed ID: 16764600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guidelines for the use of recombinant human erythropoietin.
    Barosi G; Cazzola M; De Vincentiis A; Grossi A; Tura S
    Haematologica; 1994; 79(6):526-33. PubMed ID: 7896210
    [No Abstract]   [Full Text] [Related]  

  • 5. Anemia therapy: individual benefit and societal cost.
    Denton TA; Diamond GA; Matloff JM; Gray RJ
    Semin Oncol; 1994 Apr; 21(2 Suppl 3):29-35. PubMed ID: 8202723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy.
    Anand A; Anand A; Anand N
    Cancer; 1996 May; 77(9):1960-1. PubMed ID: 8646701
    [No Abstract]   [Full Text] [Related]  

  • 7. PHARMAC and erythropoietin for cancer patients.
    Grocott R; Metcalfe S; Moodie P
    N Z Med J; 2006 Jun; 119(1236):U2039. PubMed ID: 16807581
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-utility analysis of recombinant human erythropoietin in anemic cancer patients induced by chemotherapy in Thailand.
    Roungrong J; Teerawattananon Y; Chaikledkaew U
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S119-25. PubMed ID: 19255987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EPO in cancer anemia: benefits and potential risks.
    Milano M; Schneider M
    Crit Rev Oncol Hematol; 2007 May; 62(2):119-25. PubMed ID: 17197190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human erythropoietin beta therapy: an effective strategy to reduce transfusion requirement in children receiving anticancer treatment.
    Corapcioglu F; Aksu G; Basar EZ; Demirel A; Oncel S; Mutlu A
    Pediatr Hematol Oncol; 2008 Sep; 25(6):509-21. PubMed ID: 18728970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comments on Clinical and economic comparison of epoetin alfa and darbepoetin alfa.
    Sullivan SD
    Curr Med Res Opin; 2004 Sep; 20(9):1461; author reply 1462-3. PubMed ID: 15487107
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia.
    Cremieux PY; Finkelstein SN; Berndt ER; Crawford J; Slavin MB
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):459-72. PubMed ID: 10662393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: an integrated analysis of the Canadian experience.
    Quirt I; Kovacs M; Couture F; Turner AR; Noble M; Burkes R; Dolan S; Plante RK; Lau CY; Chang J
    Oncologist; 2006 Jan; 11(1):73-82. PubMed ID: 16401716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of mild anemia.
    Waltzman RJ
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 3():S-38-41. PubMed ID: 23570098
    [No Abstract]   [Full Text] [Related]  

  • 15. What are cancer patients willing to pay for prophylactic epoetin alfa?--A cost-benefit analysis.
    Orhan B; Yalçin S
    Cancer; 1999 Sep; 86(6):1095-6. PubMed ID: 10491539
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of epoetin in the management of anaemia in patients with lung cancer.
    Morère JF
    Lung Cancer; 2004 Nov; 46(2):149-56. PubMed ID: 15474662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Zealand cancer patients should have access to erythropoietin treatment.
    Carter J; Clay J
    N Z Med J; 2006 May; 119(1234):U1989. PubMed ID: 16718300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epoetin beta therapy in patients with solid tumours.
    Pronzato P; Jassem J; Mayordomo J
    Crit Rev Oncol Hematol; 2006 Apr; 58(1):46-52. PubMed ID: 16169242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Use of erythropoietin in the treatment of cancer-related anemia].
    Huang JX; Meng FJ
    Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):877-8. PubMed ID: 22335959
    [No Abstract]   [Full Text] [Related]  

  • 20. Economics of epoetin therapy.
    Grimm AM; Flaharty KK; Hopkins LE; Mauskopf J; Besarab A; Vlasses PH
    Clin Pharm; 1989 Nov; 8(11):807-10. PubMed ID: 2509130
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.